Obermeyer Wealth Partners’s Albany Molecular Research Inc AMRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
– Sell
-373,802
Closed -$8.11M – 131
2017
Q2
$8.11M Sell
373,802
-1,364,962
-79% -$24.8M 0.72% 32
2017
Q1
$24.4M Sell
1,738,764
-14,539
-0.8% -$238K 2.25% 22
2016
Q4
$32.9M Sell
1,753,303
-48,470
-3% -$824K 3.15% 13
2016
Q3
$29.7M Buy
1,801,773
+13,730
+0.8% +$203K 2.85% 13
2016
Q2
$24M Buy
1,788,043
+39,893
+2% +$582K 2.39% 18
2016
Q1
$26.7M Buy
1,748,150
+80,485
+5% +$1.26M 2.48% 16
2015
Q4
$33.1M Buy
1,667,665
+58,237
+4% +$1.11M 3.02% 14
2015
Q3
$28M Buy
1,609,428
+119,254
+8% +$2.43M 2.95% 12
2015
Q2
$30.1M Buy
1,490,174
+92,301
+7% +$1.78M 2.57% 14
2015
Q1
$24.6M Buy
1,397,873
+1,096,870
+364% +$18.7M 2.01% 14
2014
Q4
$4.9M Buy
+301,003
New +$5.52M 0.44% 55

Other funds holding AMRI

Obermeyer Wealth Partners's AMRI Position: Q3 2017 in Review

Obermeyer Wealth Partners sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 373,802 shares — an estimated $8.11M sold.

Obermeyer Wealth Partners first reported a position in AMRI in Q4 2014 and held it in 11 quarters. The position peaked at $33.1M in Q4 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Obermeyer Wealth Partners reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Obermeyer Wealth Partners sold 373,802 Albany Molecular Research Inc shares in Q3 2017, an estimated $8.11M.
  • Obermeyer Wealth Partners first reported a position in Albany Molecular Research Inc in Q4 2014 and held it in 11 quarters.
  • Obermeyer Wealth Partners's Albany Molecular Research Inc position peaked at $33.1M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Obermeyer Wealth Partners's 13F filing for Q3 2017, filed 2 Nov 2017.